株探米国株
日本語 英語
エドガーで原本を確認する
0001773751false00017737512023-05-082023-05-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2023

HIMS & HERS HEALTH, INC.
(Exact name of registrant as specified in its charter)
 
Delaware   001-38986 98-1482650
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
(IRS Employer
Identification No.)
2269 Chestnut Street, #523
94123
San Francisco ,
California
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code:  (415) 851-0195

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each class Trading symbol Name of each exchange on which registered
Class A common stock, $0.0001 par value HIMS New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 





Item 2.02. Results of Operations and Financial Condition.
On May 8, 2023, Hims & Hers Health, Inc. (the "Company") issued a press release announcing its results of operations for the quarter ended March 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 2.02.
The information in this Current Report on Form 8-K and Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.
Description
99.1   
104 Cover Page Interactive Data file (embedded within the Inline XBRL document)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HIMS & HERS HEALTH, INC.
DATE: May 8, 2023
By: /s/ Oluyemi Okupe
Oluyemi Okupe
Chief Financial Officer
(Principal Financial Officer)


EX-99.1 2 hims-20230331x8xkearningre.htm EX-99.1 Document


Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

Revenue of $190.8 million, up 88% year-over-year in Q1 2023

Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023

Subscribers grew to over 1.2 million, up 87% year-over-year in Q1 2023

Raises full year 2023 revenue guidance to a range of $810 million to $830 million and Adjusted EBITDA guidance to a range of $25 million to $30 million


SAN FRANCISCO, May 8, 2023 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the first quarter ended March 31, 2023.

“We are pleased with our outstanding performance in the first quarter, as our ability to deliver more personalized and accessible products and services is inspiring more customers to take better care of their health and well-being,” said Andrew Dudum, co-founder and CEO. “Our significant market opportunity, robust consumer demand and consistent execution across our four strategic pillars – trusted brand, leading technology, product innovation and clinical excellence – uniquely positions us as a trusted market leader.”

“Our resilient customer base and durable recurring revenue model is operating at a scale that enables us to generate high growth while generating incremental efficiencies,” said Yemi Okupe, CFO. “These dynamics enable us to unlock our market opportunity from a position of strength and we expect to continue delivering leading innovation and access to care to our customers to capitalize on our growth momentum while driving operational excellence.”





Key Business Metrics
(In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)
Three Months Ended March 31,
2023 2022 % Change
Subscribers (end of period) 1,209  646  87  %
Monthly Online Revenue per Average Subscriber $ 55  $ 52  %
Net Orders 2,047  1,207  70  %
AOV $ 90  $ 78  15  %

Revenue
(In Thousands, Unaudited)
Three Months Ended March 31,
2023 2022 % Change
Online Revenue $ 184,175  $ 94,102  96  %
Wholesale Revenue 6,595  7,212  (9) %
Total revenue $ 190,770  $ 101,314  88  %

First Quarter 2023 Financial Highlights
•Revenue was $190.8 million for the first quarter of 2023 compared to $101.3 million for the first quarter of 2022, an increase of 88% year-over-year.
•Gross margin was 80% for the first quarter of 2023 compared to 74% for the first quarter of 2022.
•Net loss was $(10.1) million for the first quarter of 2023 compared to $(16.3) million for the first quarter of 2022.
•Adjusted EBITDA was $6.1 million for the first quarter of 2023 compared to $(6.1) million for the first quarter of 2022.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States (“U.S. GAAP”), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook

Hims & Hers provides guidance based on current market conditions and expectations for revenue and Adjusted EBITDA, which is a non-GAAP financial measure.

For the second quarter 2023, we expect:
•Revenue of $200 million to $205 million.
•Adjusted EBITDA of $4 million to $7 million, reflecting an Adjusted EBITDA margin of 2% to 3%.

For the full year 2023, we expect:
•Revenue of $810 million to $830 million.
•Adjusted EBITDA of $25 million to $30 million, reflecting an Adjusted EBITDA margin of 3% to 4%.




The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the first quarter 2023 results on May 8, 2023, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.forhims.com/.




Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believe,” “estimate,” “anticipate,” “expect,” “assume,” “imply,” “intend,” “plan,” “may,” “will,” “potential,” “project,” “predict,” “continue,” “could,” or “should,” or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, our market opportunity, investments in innovation, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our categories, our ability to innovate on and expand the scope of our offerings and experiences, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer product quality laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Risk Factors” section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission.



In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

As our business grows and evolves, we continually and strategically review our key metrics. Beginning with our 2022 Annual Report on Form 10-K, we commenced reporting “Subscribers” and “Monthly Online Revenue Per Average Subscriber” as additional key business metrics (as defined below). As a result of broadening the number of health and wellness categories we serve, we believe it is important to measure the holistic relationship that we have with our customers. Additionally, the recurring nature of our revenue necessitates the need for metrics that provide greater visibility into both the breadth and engagement of users on our platform. We believe Subscribers represent a more accurate reflection of the number of distinct users that we have on our platform relative to the number of subscriptions, and beginning with the three months ending March 31, 2023, we are no longer reporting “Subscriptions” as a key business metric. Monthly Online Revenue per Average Subscriber reflects how users’ engagement with products across our platform is evolving. These changes are intended to better align our key business metrics with our internal priorities and business plans.

“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. We sell only non-prescription products to wholesale partners. In addition to being revenue generative and profitable, wholesale partnerships have the added benefit of generating brand awareness with new customers in physical environments.

“Subscribers” are customers who have one or more “Subscriptions”, which are agreements pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of months (for example, billed every month or every three months), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel Subscriptions in between billing periods to stop receiving additional products and services and can reactivate Subscriptions to continue receiving additional products and services.

“Monthly Online Revenue per Average Subscriber” is defined as Online Revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.




“Net Orders” are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

Average Order Value (“AOV”) is defined as Online Revenue divided by Net Orders.



CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share and Per Share Data, Unaudited)
March 31, 2023 December 31, 2022
(Unaudited)
Assets
Current assets:
Cash and cash equivalents $ 48,745  $ 46,772 
Short-term investments 135,648  132,853 
Inventory 20,697  21,562 
Prepaid expenses and other current assets 20,435  15,408 
Total current assets 225,525  216,595 
Restricted cash 856  856 
Goodwill 110,881  110,881 
Intangibles, net 20,909  21,841 
Operating lease right-of-use assets 4,548  4,936 
Other long-term assets 13,587  11,232 
Total assets $ 376,306  $ 366,341 
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $ 37,609  $ 32,363 
Accrued liabilities 14,121  12,448 
Deferred revenue 2,866  1,472 
Operating lease liabilities 1,687  1,658 
Total current liabilities 56,283  47,941 
Operating lease liabilities 3,217  3,649 
Earn-out liabilities 3,977  2,975 
Other long-term liabilities 84  35 
Total liabilities 63,561  54,600 
Commitments and contingencies
Stockholders' equity:
Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 200,934,421 and 200,051,689 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of March 31, 2023 and December 31, 2022
21  21 
Additional paid-in capital 667,531  656,626 
Accumulated other comprehensive loss (111) (277)
Accumulated deficit (354,696) (344,629)
Total stockholders' equity 312,745  311,741 
Total liabilities and stockholders' equity $ 376,306  $ 366,341 



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In Thousands, Except Share and Per Share Data, Unaudited)
Three Months Ended March 31,
2023 2022
Revenue $ 190,770  $ 101,314 
Cost of revenue 37,345  26,558 
Gross profit 153,425  74,756 
Gross margin % 80  % 74  %
Operating expenses:(1)
Marketing 97,245  48,093 
Operations and support 26,182  15,683 
Technology and development 10,748  6,088 
General and administrative 30,513  21,811 
Total operating expenses 164,688  91,675 
Loss from operations (11,263) (16,919)
Other income:
Change in fair value of liabilities (295) 441 
Other income, net 1,877  320 
Total other income, net 1,582  761 
Loss before income taxes (9,681) (16,158)
Provision for income taxes (386) (94)
Net loss (10,067) (16,252)
Other comprehensive income (loss) 166  (186)
Total comprehensive loss $ (9,901) $ (16,438)
Net loss per share attributable to common stockholders:
Basic and diluted $ (0.05) $ (0.08)
Weighted average shares outstanding:
Basic and diluted 207,140,298  202,695,970 
______________ 
(1)Includes stock-based compensation expense as follows (in thousands):


Three Months Ended March 31,
2023 2022
Marketing $ 996  $ 823 
Operations and support 1,154  486 
Technology and development 1,461  906 
General and administrative 10,556  6,641 
Total stock-based compensation expense $ 14,167  $ 8,856 





CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands, Unaudited)
Three Months Ended March 31,
2023 2022
Operating activities
Net loss $ (10,067) $ (16,252)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 2,117  1,741 
Stock-based compensation 14,167  8,856 
Change in fair value of liabilities 295  (441)
Net (accretion) amortization on securities (1,041) 971 
Provision (benefit) for deferred taxes 49  (112)
Impairment of long-lived assets 429  — 
Non-cash operating lease cost 448  377 
Non-cash acquisition-related costs 566  69 
Non-cash other 75  (163)
Changes in operating assets and liabilities:
Inventory 865  1,415 
Prepaid expenses and other current assets (4,984) (7,677)
Other long-term assets (30)
Accounts payable 3,955  4,266 
Accrued liabilities 1,673  (3,148)
Deferred revenue 1,394  (2,043)
Operating lease liabilities (463) (384)
Earn-out payable —  (6,848)
Net cash provided by (used in) operating activities 9,483  (19,403)
Investing activities
Purchases of investments (40,687) (84,881)
Maturities of investments 39,084  82,340 
Proceeds from sales of investments —  22,291 
Investment in website and mobile application development and internal-use software (1,875) (1,197)
Purchases of property, equipment, and intangible assets (635) (100)
Net cash (used in) provided by investing activities (4,113) 18,453 
Financing activities
Proceeds from exercise of vested stock options 245  891 
Payments for taxes related to net share settlement of equity awards (3,657) (404)
Payments for earn-out consideration for acquisitions —  (23,014)
Net cash used in financing activities (3,412) (22,527)
Foreign currency effect on cash and cash equivalents 15  (23)
Increase (decrease) in cash, cash equivalents, and restricted cash 1,973  (23,500)
Cash, cash equivalents, and restricted cash at beginning of period 47,628  72,640 
Cash, cash equivalents, and restricted cash at end of period $ 49,601  $ 49,140 
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents $ 48,745  $ 48,284 
Restricted cash 856  856 
Total cash, cash equivalents, and restricted cash $ 49,601  $ 49,140 
Supplemental disclosures of cash flow information
Cash paid for taxes $ 286  $ 36 
Non-cash investing and financing activities
Purchase of property and equipment included in accounts payable $ 1,290  $ — 
Vesting of early exercised stock options —  38 



Non-GAAP Financial Measures
In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), and Adjusted EBITDA margin (which is a non-GAAP ratio), each as defined below. We use Adjusted EBITDA and Adjusted EBITDA margin to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA and Adjusted EBITDA margin to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA and Adjusted EBITDA margin is helpful to our investors as they are used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA or Adjusted EBITDA margin as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net loss before stock-based compensation, depreciation and amortization, acquisition-related costs (which includes consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses), impairment of long-lived assets, income taxes, change in fair value of liabilities, and interest income. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net loss and other U.S. GAAP results.




Net Loss to Adjusted EBITDA Reconciliation
(In Thousands, Unaudited)
Three Months Ended March 31,
2023 2022
Revenue $ 190,770  $ 101,314 
Net loss (10,067) (16,252)
Stock-based compensation 14,167  8,856 
Depreciation and amortization 2,117  1,741 
Acquisition-related costs 646  116 
Impairment of long-lived assets 429  — 
Provision for income taxes 386  94 
Change in fair value of liabilities 295  (441)
Interest income (1,913) (175)
Adjusted EBITDA $ 6,060  $ (6,061)
Net loss as a % of revenue (5) % (16) %
Adjusted EBITDA margin % (6) %


Contacts:
Investor Relations
Alice Lopatto
Investors@forhims.com

Media Relations
Press@forhims.com